Table 3.
Twenty most significant canonical pathways expressed in satellite cell cultures at 38°C after 48 h of differentiation.
| RBC2 | F-Line | |||
|---|---|---|---|---|
| Metabolic Pathways | −log (p-value) | Ratio | −log (p-value) | Ratio |
| tRNA charging | 8.920 | 0.846 | 8.950 | 0.846 |
| Superpathway of inositol phosphate compounds | 6.870 | 0.540 | 7.260 | 0.545 |
| 3-phosphoinositide degradation | 6.860 | 0.582 | 6.540 | 0.575 |
| Colanic acid building blocks biosynthesis | 6.050 | 1.000 | 6.070 | 1.000 |
| 3-phosphoinositide biosynthesis | 5.960 | 0.543 | 6.020 | 0.543 |
| D-myo-inositol (1,4,5,6)-tetrakisphosphate biosynthesis | 5.720 | 0.574 | 5.770 | 0.574 |
| D-myo-inositol (3,4,5,6)-tetrakisphosphate biosynthesis | 5.720 | 0.574 | 5.770 | 0.574 |
| D-myo-inositol-5-phosphate metabolism | 4.930 | 0.544 | 4.980 | 0.544 |
| Superpathway of D-myo-inositol (1,4,5)-trisphosphate metabolism | 4.860 | 0.800 | 5.750 | 0.840 |
| Fatty Acid β-oxidation I | 4.200 | 0.719 | 3.600 | 0.688 |
| Valine degradation I | 4.130 | 0.833 | 4.140 | 0.833 |
| Pyridoxal 5′-phosphate salvage pathway | 3.660 | 0.594 | 3.680 | 0.594 |
| Superpathway of cholesterol biosynthesis | 3.650 | 0.714 | 3.670 | 0.714 |
| Isoleucine degradation I | 3.590 | 0.857 | 3.600 | 0.857 |
| TCA Cycle II (Eukaryotic) | 3.460 | 0.739 | 3.470 | 0.739 |
| D-myo-inositol (1,4,5)-trisphosphate degradation | 3.300 | 0.778 | 4.140 | 0.833 |
| D-myo-inositol (1,3,4)-trisphosphate biosynthesis | 3.210 | 0.750 | 3.990 | 0.800 |
| Phosphatidylglycerol biosynthesis II (Non-plastidic) | 3.080 | 0.692 | 3.090 | 0.692 |
| Salvage pathways of pyrimidine ribonucleotides | 2.850 | 0.527 | 2.880 | 0.527 |
| GDP-mannose biosynthesis | 2.590 | 1.000 | 2.600 | 1.000 |
| SIGNALING PATHWAYS | ||||
| Protein ubiquitination pathway | 25.400 | 0.694 | 25.500 | 0.694 |
| EIF2 signaling | 24.100 | 0.732 | 24.200 | 0.732 |
| Regulation of eIF4 and p70S6K signaling | 18.400 | 0.720 | 18.500 | 0.720 |
| mTOR signaling | 16.000 | 0.658 | 16.600 | 0.663 |
| NRF2-mediated oxidative stress response | 15.500 | 0.658 | 15.100 | 0.653 |
| Estrogen receptor signaling | 12.600 | 0.688 | 12.700 | 0.688 |
| Molecular mechanisms of cancer | 12.600 | 0.553 | 12.700 | 0.553 |
| Hereditary breast cancer signaling | 12.400 | 0.669 | 12.500 | 0.669 |
| Aldosterone signaling in epithelial cells | 12.300 | 0.645 | 12.400 | 0.645 |
| Huntington's disease signaling | 11.500 | 0.589 | 11.600 | 0.589 |
| Role of BRCA1 in DNA damage response | 10.700 | 0.744 | 10.800 | 0.744 |
| PI3K/AKT signaling | 10.400 | 0.661 | 10.500 | 0.661 |
| Death receptor signaling | 9.090 | 0.685 | 9.730 | 0.696 |
| Integrin signaling | 9.000 | 0.571 | 9.830 | 0.580 |
| AMPK | 8.660 | 0.582 | 8.730 | 0.582 |
| Protein kinase A signaling | 8.630 | 0.515 | 8.460 | 0.513 |
| Mitotic roles of polo-like kinase | 8.440 | 0.727 | 8.480 | 0.727 |
| Glioma signaling | 8.420 | 0.645 | 8.470 | 0.645 |
| HIPPO signaling | 8.040 | 0.674 | 8.090 | 0.674 |
| Apidogenesis pathway | 8.000 | 0.612 | 8.060 | 0.612 |